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It has been long known that hepatic synthesis of phosphatidylcholine (PC) is depressed dur-
ing acute such as carbon tetrachloride-induced liver injury. Anti-hepatotoxic properties of PC
as liposomes have been recognized for treatment of acute liver damage. Ursodeoxycholate
(UDCA) is a known hepatoprotectant in stabilizing cellular membrane. For therapeutic man-
agement of liver injury, we coupled UDCA with a phospholipid known as ursodeoxycholyl
lysophosphatidylethanolamide (UDCA-LPE). UDCA-LPE has been shown to ﬁrst-in-class
hepatoprotectant being superior to UDCA or PC. It inhibits mitochondrial damage and
apoptosis, elicits survival signaling pathway, and promotes regeneration of hepatocytes.
We herein report that a unique contribution of UDCA-LPE in increasing concentrations of
PC in vitro and in vivo. UDCA-LPE-treated hepatocytes contained signiﬁcantly increased
PC levels. UDCA-LPE underwent the hydrolysis to LPE which was not the precursor of the
increased PC.The levels of PC in the liver and blood were increased rapidly after intraperi-
toneally administration UDCA-LPE, and were found to be sustained even after 24 h. Among
PC synthesis genes tested, UDCA-LPE treatment of mouse hepatocytes increased tran-
scription of CDP-diacylglycerol synthase 1 which is an enzyme catalyzing phosphatidic acid
to generate intermediates for PC synthesis. Thus, UDCA-LPE as a hepatoprotectant was
able to induce synthesis of protective PC which would supplement for the loss of PC occur-
ring during acute liver injury. This property has placed UDCA-LPE as a candidate agent for
therapy of acute hepatotoxicity such as acetaminophen poisoning.
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INTRODUCTION
Phospholipids including lecithins and phosphatidylcholine (PC)
have been used and tested in humans for treatment of liver dis-
ease since the 1970s (Wallnofer and Hanusch, 1973). PC is the
major membrane phospholipids and thus their hepatoprotec-
tive effects are due to membrane stabilization (Miyazaki et al.,
1991) as well as enhancement of cell membrane integrity (Li
et al., 2006). Research on phospholipid biochemistry in the
past three decades has revealed physiological role of PC which
is required for hepatocellular division and survival (Jackowski,
1994), and that alterations of PC homeostasis could result in
development of liver diseases (Noga and Vance, 2003; Li et al.,
2005).
Abbreviations: BSA, bovine serum albumin; CDS1, CDP-diacylglycerol syn-
thase 1; LC/MS, liquid chromatography mass spectrometry; LPE, 1-18:1
lysophosphatidylethanolamine; Pal, palmitate; PC, phosphatidylcholine; PE, phos-
phatidylethanolamine; PPAR, peroxisome proliferator-activated receptor; PS,
phosphatidylserine; UDCA, ursodeoxycholic acid; UDCA-LPE, ursodeoxycholyl
lysophosphatidylethanolamide.
Hepatoprotective role of PC is applicable not only for chronic
liver disease but also for acute liver damage. It was found
nearly 50 years ago that carbon tetrachloride (CCl4) intoxica-
tion is associated with changes in composition of PC and phos-
phatidylethanolamine (PE; Sgoutas, 1967; Shimizu, 1969; Sug-
ano et al., 1970). Total phospholipids in hepatic microsomes
(Sgoutas, 1967), endoplasmic reticulum (James et al., 1982), and
plasma membrane (Camacho and Rubalcava, 1984) are markedly
depressed followingCCl4 administration of experimental animals.
This is due to decreased syntheses of both phospholipids and
triglycerides readily observed 4–5 h after treatment (Gebhart and
Brabec, 1985). CCl4-induced injury in vivo produces an early per-
oxidative event from the generation of trichloromethyl radical as a
result of cytochrome P450-mediated metabolism of CCl4 (Trudell
et al., 1982). These free radicals react with cellular PC forming
PC-derived lipid radicals which subsequently react with oxygen
to form PC hydroperoxides (Miyazawa et al., 1990). The forma-
tion of PC hydroperoxides is indicative of hepatic injury causing
alterations in membrane structure. For treatment, it is conceivable
that a supplementation of PC during acute liver injury replenishes
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PC levels which can serve as both structural components, and tar-
gets for trichloromethyl free radical binding (Jaeschke et al., 1987).
Indeed, administration of PC to experimental animals intoxicated
with acetaminophen (Jaeschke et al., 1987), CCl4 (Aleynik et al.,
1997), alcohol (Okiyama et al., 2009), or infected with sepsis-
induced bacteria (Yan et al., 2004), has been proven to be effective
in alleviating liver injury.
To date, therapeutic use of PC to treat liver disease in humans
has however not been successful (Lieber et al., 2003). As exoge-
nously added PC can provide only ∼50% of the PC required for
membrane biogenesis (Esko et al., 1982), the amount of PC taken
up into hepatocytes may be limited thus providing not enough
PC needed for membrane protection. For treatment of acute liver
injury, antioxidants such as acetylcysteine to treat acetaminophen
overdose have been commonly used (Green et al., 2010). Alter-
natively, manipulation of metabolic pathways to increase PC lev-
els has been adopted for treatment of acute liver injury. These
strategies include the use of PC precursors, such as, betaine (Khar-
banda et al., 2007), ﬁsh oils (Speck and Lauterburg, 1991), dietary
saturated and monounsaturated fats (Hwang et al., 2011), and
agonists of the peroxisome proliferator-activated receptor (PPAR)
alpha (Lee et al., 2004). At least in experimental settings, both
administration of PC and the modulation of pathways to increase
PC have currently provided positive results in ameliorating acute
hepatotoxicity.
We had synthesized a hepatoprotectant ursodeoxycholyl
lysophosphatidylethanolamide (UDCA-LPE, Chemical structure
shown in Figure 1A), which as an intact compound provides
cytoprotection against TNF-alpha-induced apoptosis (Chamuli-
trat et al., 2009). UDCA-LPE lowers aminotransferases and
elicits anti-inﬂammatory response in mice treated with galac-
tosamine/endotoxin (Pathil et al., 2011a) or fed with high-fat diet
(Pathil et al., 2011b). UDCA-LPE as a hepatoprotectant may thus
potentially be used to treat acute liver injury. Herein, we provided
evidence that UDCA-LPE induced elevation of hepatocellular PC
levels under in vitro and in vivo conditions. This is in part due to
UDCA-LPE’s ability to elicit transcriptional control of a PC syn-
thesis gene phosphatidate cytidylyltransferase or another name
CDP-diacylglycerol synthase 1 (CDS1). The ability of UDCA-LPE
to rapidly increase hepatic PC levels renders it suitable to treat
FIGURE 1 | Ursodeoxycholyl lysophosphatidylethanolamide hydrolysis
to LPE and increases PC concentrations in mouse hepatocytes. (A)
Chemical structure of UDCA-LPE (UDCA-18:1-LPE). (B) Upon treatment with
50μM UDCA-LPE, UDCA-LPE was taken to hepatocytes over 4–12 h. (C)
Upon treatment with 50μM UDCA-LPE, LPE concentrations were increased
after 12 h treatment indicating that UDCA-LPE hydrolysis occurred at 12 h but
not at 4 h. (D)Total PC (diacyl PC and lyso PC) concentrations were increased
mouse hepatocytes treated with 50μM UDCA-LPE for 4 and 20 h. “Con”
represents control hepatocytes treated with ethanol used as a vehicle. Data
are mean±SD, N =4; *p<0.05 versus control.
Frontiers in Physiology | Gastrointestinal Sciences February 2012 | Volume 3 | Article 24 | 2
Chamulitrat et al. Improved PC homeostasis by UDCA-LPE
acute hepatotoxicity in clinical settings, such as, acetaminophen
poisoning.
MATERIALS AND METHODS
MATERIALS
Ursodeoxycholyl lysophosphatidylethanolamide was synthesized
by ChemCon GmbH (Freiburg, Germany). UDCA was purchased
from Sigma-Aldrich (St. Louis, MO, USA). Phospholipid stan-
dards (1-oleoyl-2-hydroxy-sn-glycero-3-phosphoethanolamine
(18:1-lyso PE), 1-palmitoyl-2-hydroxy-sn-glycero-3-phosphocho
line (16:0-lyso PC), 1-stearoyl-2-hydroxy-sn-glycero-3-phospho-
choline (18:0-lyso PC), 1-oleoyl-2-hydroxy-sn-glycero-3-phospho
choline (18:1-lyso PC), 1-arachidonyl-2-hydroxy-sn-glycero-3-
phosphocholine (20:4-lyso PC) 1-palmitoyl-2-oleoyl-sn-glycero-
3-phospho-choline (16:0, 18:1-PC), 1-palmitoyl-2-linoleoyl-
sn-glycero-3-phosphocholine (16:0, 18:2-PC), 1-palmitoyl-2-
arachidonoyl-sn-glycero-3-phosphocholine (16:0, 20:4-PC), 1-
stearoyl-2-oleoyl-sn-glycero-3-phosphocholine (18:0, 18:1-PC),
1-stearoyl-2-linoleoyl-sn-glycero-3-phosphocholine (18:0, 18:2-
PC),and1-palmitoyl(d31)-2-oleoyl-sn-glycero-3-phos-phocholine
(d31-16:0, 18:1-PC) were obtained from Avanti Lipids, Inc.
(Alabaster, AL, USA) and were at least 99% pure. All other sol-
vents and chemicals used were of either high-performance-liquid-
chromatography grade or of known analytical purity and obtained
from Sigma-Aldrich (St. Louis, MO, USA).
ANIMAL EXPERIMENTS
Male C57BL/6 mice (Charles River Laboratories, Sulzfeld, Ger-
many) at 10 weeks old received 30 mg/kg UDCA-LPE by intraperi-
toneal injections. UDCA-LPE was dissolved in 0.5% car-
boxymethylcellulose.At designated time, eachmouse for each time
point was sacriﬁced. Blood, liver, and intestine were collected for
lipid extraction and LC–MS/MS analysis. All experiments were
approved by theAnimal Care andUseCommittee of theUniversity
Heidelberg.
HEPATOCYTE ISOLATION AND CULTURES
Hepatocytes were isolated from 7- to 10-week-old C57/BL6 mice
(Charles Rivers Laboratories, Sulzfeld, Germany) by using two-
step collagenase perfusion technique and puriﬁed by Percoll gra-
dient centrifugation. Freshly isolated hepatocytes were plated on
multi-well collagen-coated plates and cultured for 4 h in M199
medium containing Hank’ salts and l-glutamine (PAA, Cölbe,
Germany) supplement with 1% penicillin and streptomycin,
100 nM dexamethasone, 0.5 nM insulin, and 5% neonatal calf
serum. Dead hepatocytes were removed, and the adhered cells
were treated with serum-free medium. After overnight in culture,
hepatocytes were treated with UDCA-LPE in serum-free M199
medium for 4 or 12 h. Ethanol as a vehicle of UDCA-LPE was
added in the control groups.
PALMITATE-INDUCED APOPTOSIS
Pal stock solution in BSA was prepared. Brieﬂy, 250 μL of 200 mM
Pal in ethanol wasmixedwith 4.5 mL of 27%BSA in PBS. The total
5 mL volume was adjusted to pH to 7.4 with 0.1 N NaOH until the
mixture became clear. The appropriate control for Pal treatment
contained 0.5% BSA and 0.1% ethanol. For apoptosis assays, cas-
pase 3/7glo assay kits (Promega, Mannheim, Germany) were used
as previously described (Chamulitrat et al., 2009). Incubation time
for apoptosis assay was 20 h.
PREPARATION OF STANDARDS AND SAMPLES FOR LC–MS/MS
ANALYSIS
Phosphatidylcholine standards obtained from Avanti Lipids are in
chloroform at a concentration of 10 mg/mL. They were diluted to
100 ng/μL with methanol and used as working solutions. Stock
solutions of 18:1-lyso PE (1 mg/mL) was prepared in chloro-
form:methanol (1:4, v/v) and stored at −20˚C. UDCA and d4-
UDCA stock solution (1 mg/mL) was prepared in methanol and
stored at −20˚C. Working solutions were prepared by appropriate
dilution of the stock solutions with methanol. Calibration curves
were constructed forUDCA-LPE,UDCA, and LPE in PBS solution
using d4-UDCA as internal standard and curve range was in 0–
50 ng. Calibration curve of each individual PC was built using d31-
16:0–18:1-PC as an internal standard. The linear response for PC
and lyso PC was in the range of 0–200 and 0–100 ng, respectively.
Hepatocytes treated with UDCA-LPE (in 20μL suspension)
was added with 180μL H2O, and 20μL of 0.5 ng/μL d4-UDCA,
and then extracted with 1 mL CHCl3:MeOH (2:1) twice. The
chloroform layer was dried down and reconstituted into 200μL
MeOH, and 20μL was injected onto the HPLC column. Mouse
plasma and urine samples were treated with the same procedure
as for hepatocytes. For analyses of tissue samples, homogenates
were prepared in PBS to give a ﬁnal concentration of 1 g/mL d4-
UDCA (0.5 ng/μL, 20μL) and d31-16:0–18:1-PC (2 ng/μL, 20μL)
were added to the homogenates and subsequent lipid extraction
with CHCl3:MeOH was performed.
LC–MS/MS ANALYSIS OF UDCA-LPE AND PHOSPHOLIPIDS
LC–MS/MS analysis was carried out on a Waters Quattro Micro
API triple quadrupole mass spectrometer (Milford, MA, USA)
interfaced with Acquity UPLC system. Nitrogen was used as
nebulizer and argon was used as collision gas. Optimized mass
spectrometry parameters were determined with individual stan-
dard compounds. UDCA-LPE and LPE analysis were performed
under negative mode with multiple reactions monitoring (MRM)
mass transitions set at 852.5> 281.3, 478.2> 281.2, 391.1> 391.1
respectively. Quantiﬁcation of diacyl PC and lyso PC were per-
formed under positive mode, monitoring transition pair of the
individual protonated parent ions for PCs and their common
daughter ion m/z 184. Total PC was the sum of diacyl PC and
lyso PC.
Online chromatographic separation was achieved using a 100-
mm× 2.0-mm i.d. Luna 3μ C18 column (Phenomenex, CA,
USA). Binary solvents used for analysis were 95% H2O/MeOH
with 2 mM ammonium acetate (solvent A) and 95% MeOH/H2O
with 2 mM ammonium acetate (solvent B). For analysis of UDCA-
LPE and LPE, gradient started with 90% solvent A for 1 min,
changed to 100% solvent B in 0.5 min, held for 5 min, and ﬁnally
switched back to initial condition in 0.1 min. The total analysis
time was 8 min. Gradient for PC analysis started with 85% solvent
B and was maintained for 1 min. Then rose in 0.5 min linearly to
100% solvent B. The elution was held at 100% B for 10 min, then
reversed to 85% methanol in 0.5 min. The 3-min holding at 85%
methanol equilibrated the column efﬁciently. Flow rate for both
analyses was 0.2 mL/min.
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GENE EXPRESSION BY REAL-TIME RT-PCR
Total RNA of treated mouse hepatocytes was isolated using QIA-
GEN RNeasy Mini kit (Qiagen, Hilden, Germany). cDNA was
synthesized from 2μg RNA using a Maxima First Strand cDNA
synthesis kit (Fermentas, St. Leon-Rot, Germany). The mRNA
expression was analyzed in quadruplets by real-time PCR using
Applied Biosystems TaqMan® gene expression assays with Taq-
Man® Universal PCR Master Mix (Applied Biosystems) and run
on an Applied Biosystem 7500 Fast real-time PCR machine by
using assay-on-Demand TaqMan® primers. The expression level
of targets was calculated using Δ−C t transformation method, and
showed as ratio after having been normalized to house-keeping
gene GAPDH. PCR results were obtained from at least three
independent experiments.
DATA ANALYSIS
Statistical signiﬁcance at p> 0.05 was determined withANOVA or
a Student’s t -test using Primer Biostatistics. Results were expressed
as mean± SD.
RESULTS
UDCA-LPE INCREASES PC CONCENTRATIONS IN MOUSE HEPATOCYTES
Intracellular concentrations of UDCA-LPE (chemical structure
shown in Figure 1A) in mouse hepatocytes were increased from 20
to 80 pmol/mg protein with 40 or 60 μM UDCA-LPE (Figure 1B).
At the same time, intracellular concentrations of LPE were not yet
increased at 4 h butmarkedly increased after 12 h by∼15 pmol/mg
protein (Figure 1C).
Cellular concentrations of PC were elevated in mouse hepa-
tocytes treated with 40 or 60μM UDCA-LPE for 4 or 12 h
(Figure 1D). Comparedwith 4 h, the total PC levelswere decreased
after 12 h incubation likely due to PC export into the medium. It
is observed that the increases of total PC (diacyl PC and lyso PC)
concentrations at 4 and12 hwereon theorder of 52–54 ng/mgpro-
tein or∼150 pmol/mgprotein. The increases of LPEobserved after
12 h at ∼15 pmol/mg protein did not correspond to the increases
of PC because the increased LPE concentrations were ∼10-folds
lower than those of the observed increased PC. This excludes the
possibility that PC could arise from LPE as a result of UDCA-LPE
hydrolysis (to UDCA and LPE). Pathways for LPE conversion to
PC include acylation of LPE to PE and subsequent PE metabo-
lism to PC by PE methyltransferase (DeLong et al., 1999). Taken
together, increased PC did not arise from UDCA-LPE hydroly-
sis, and may likely be from the effects of UDCA-LPE on certain
metabolic signaling pathways which increase PC abundance.
UDCA-LPE ADMINISTRATION INCREASES PC CONCENTRATIONS
IN VIVO
We further conﬁrmed UDCA-LPE effects on PC levels under
in vivo conditions. Intraperitoneal injections of UDCA-LPE at
30 mg/kg 1 h prior to the challenge with galactosamine/endotoxin
in mice were found to be effective in alleviating acute liver injury
observed at 8 h (Pathil et al., 2011a). We therefore performed
intraperitoneal injections of 30 mg/kg UDCA-LPE over 2, 4, 8, and
24 h, and determined diacyl PC and total PC (as the sum of diacyl
PC and lyso PC). We observed that the levels of PC in plasma were
gradually increased after 2 h and stayed elevated even after 24 h
(Figure 2A). The levels of PC found in urine were increased sig-
niﬁcantly 2 h after injection, and quickly decreased to basal levels
after 4 h (Figure 2B). As urinary PC arises from PC secreted from
tissues, PC pharmacokinetics in urine indicated that PC clearance
from tissues was signiﬁcantly slowed down at the later time, i.e.,
longer than 4 h.
Similar to plasma, the levels of PC species in the liver were
signiﬁcantly elevated after 2 h and sustained at these concentra-
tions even at 24 h after administration (Figure 2C). However, PC
concentrations in the intestine were slightly increased at 6 h, and
drastically decreased at 8 and 24 h (Figure 2D). Our data clearly
demonstrated sustained increases of PC in blood and liver fol-
lowing UDCA-LPE intraperitoneal injection concomitant with
reduced PC clearance from these tissues to the urine. Signiﬁcant
increases of PC were found in the liver but not the intestine indi-
cating UDCA-LPE liver targeting, and hence demonstrating the
suitability of UDCA-LPE for treatment of liver disease.
UDCA-LPE UPREGULATES CDS1 mRNA IN MOUSE HEPATOCYTES
To determine possible activation of PC synthesis by UDCA-LPE,
we analyzed PC synthesis genes in mouse hepatocytes which had
been treated with UDCA-LPE for 4 or 20 h. UDCA-LPE treatment
for 4 h did not modulate expression of the genes under investiga-
tion (data not shown). These genes included CDP-diacylglycerol
synthase 1 (CDS1), choline kinase alpha, CDP-diacylglycerol
synthase 2 (CDS2), choline/ethanolamine phosphotransferase 1
(Cept1), choline phosphate cytidylyltransferase 1, alpha isoform
(CCTalpha or Pcyt1a), and phosphatidylethanolamine N -methyl-
transferase (PEMT). For most genes tested, UDCA-LPE had only
marginal effects (Figure 3A). However, UDCA-LPE treatment for
20 h signiﬁcantly increased mRNA expression of CDS1 by ∼1.4-
fold. CDS1 is an enzyme which converts phosphatidic acid to
phosphatidylserine (PS) intermediate and thenPEwhich is further
metabolized to generate PC by PE methyltransferase (Figure 3B).
Under apoptosis induction by palmitate exposure for 20 h, CDS1
mRNA was slightly downregulated by palmitate, and UDCA-LPE
again weakly upregulated CDS1 mRNA. (Figure 3C, left). UDCA-
LPE co-treatment with palmitate however signiﬁcantly increased
CDS1 mRNA expression by ∼5-folds. UDCA-LPE co-treatment
with palmitate did not upregulate other PC synthesis genes listed
in Figure 3A (data not shown). The increases of CDS1 mRNA
expression were concomitant with UDCA-LPE protection against
palmitate-induced apoptosis as determined by caspase 3 activity
(Figure 3C, right). Hence UDCA-LPE protection was associated
with an upregulation of CDS1 mRNA for increased PC synthesis.
DISCUSSION
Ursodeoxycholyl lysophosphatidylethanolamide is a ﬁrst-in-class
hepatoprotectant being superior to UDCA or PC capable of
inhibiting hepatocellular apoptosis (Chamulitrat et al., 2009) and
inﬂammation in vivo under acute liver injury (Pathil et al., 2011a).
PC controls liver homeostasis by membrane stabilization and the
loss of PC levels results in an on-set of development of liver disease.
It is of a questionwhetherUDCA-LPE could increase PC to replen-
ish PC for cytoprotection. We herein demonstrated that UDCA-
LPE enhanced PC concentrations in vitro and in vivo, and these
increases were associated with upregulation of CDS1. This ability
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FIGURE 2 | Ursodeoxycholyl lysophosphatidylethanolamide
increases PC levels in vivo. Mice were injected with 30mg/kg
UDCA-LPE by an intraperitoneal injection. (A) Concentrations of PC
species (total or diacyl PC) in ng/mL in plasma were increased after
2 h and stayed elevated even after 24 h. (B) Concentrations of total
PC, diacyl PC, and lyso PC in ng/mL in urine were increased after 2 h
and drastically decayed to control levels after 4 h. (C) Concentrations
of PC species in nanogram per milligram protein in the liver were
increased after 2 h and stayed elevated even after 24 h. (D)
Concentrations of total PC, and diacyl PC in ng/mg protein in the
intestine were slightly increased after 6 h and drastically decayed to
control levels after 8 h.
of UDCA-LPE to increase PC can enhance hepatoprotection and
renders it appropriate to treat acute hepatotoxicity.
We have shown that UDCA-LPE is able to induce survival
signaling pathway by activating PI3K/Akt and MAPK/ERK1/2
pathways within 0.5–7 h in cultured hepatocytes (Chamulitrat
et al., 2009). At the rapid time point of 4 h where increased PC
was observed (Figures 1 and 2), it is unlikely that UDCA-LPE
could induce PC synthesis genes on the transcriptional and trans-
lational levels. In cultured hepatocytes, the early PC response
obtainable at 4-h treatmentwithUDCA-LPEmay thus likely due to
someunknown signaling pathways triggered byUDCA-LPEwhich
result in increases of PC abundance. For such rapid activation, it
is possible that UDCA-LPE may interact with G-protein coupled
receptors on plasma membrane or nuclear receptors intracellu-
larly. The immediate PC increases were also observed in vivo 2 h
after intraperitoneal injection. Speciﬁc signaling pathways in reg-
ulating PC metabolism responsible for a rapid rise of PC have not
been identiﬁed. PPAR alpha and gamma as well as glucocorticoid
receptors are among nuclear receptors proposed to be affected by
UDCA-LPE. These receptors are known to modulate the synthe-
ses of phospholipids (Lee et al., 2004) including PC (Pan et al.,
2006). After prolonged hepatocyte treatment with UDCA-LPE for
20 h, we found that CDS1 mRNA was upregulated. CDS1 gener-
ates PC from phosphatidic acid. CDS1 upregulation could explain
the increased and sustained PC levels observed even after 24 h
under in vivo conditions. The immediate and prolonged increases
of hepatic PC levels by UDCA-LPE may provide feasibility for its
use in the clinics, for an example, for effective reduction of acute
severe hepatotoxicity from acetaminophen overdose. UDCA-LPE
may be used as an antidote against hepatotoxins in humans.
Ursodeoxycholyl lysophosphatidylethanolamide is better than
UDCA or PC in inhibiting apoptosis and liver injury (Chamulitrat
et al., 2009; Pathil et al., 2011a). PC synthesis is known to be down-
regulated during apoptosis, and that PC supplementation provides
protection (Cui and Houweling, 2002). In addition to UDCA-
LPE’s ability to inhibit apoptosis, the PC generated by UDCA-LPE
by ways of CDS1 upregulation could also be a mechanism for
its anti-apoptosis effects (Figure 3C). In support of this notion,
the contents of product of CDS1 CDP-diacylglycerol contents are
found to be decreased in livers of diabetic rats (Whiting et al.,
1977), and increased CDS1 is found during the development of
heart failure and identiﬁed to be involved in compensatory mech-
anisms (Saini-Chohan et al., 2009). These data suggest protective
function of CDS1 and consistent with UDCA-LPE protection.
In addition to UDCA (Simko and Michael, 1994), other protec-
tive bile acids, such as 5 beta-scymnol (Slitt et al., 2004), have been
shown to reduce liver injury and acetaminophen toxicity. UDCA-
LPE may be hepatoprotective in these settings as UDCA-LPE is
superior to UDCA. Furthermore,UDCA-LPE inhibits activities of
hepatic phospholipase A2 thus decreasing the levels of cytotoxic
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FIGURE 3 | Ursodeoxycholyl lysophosphatidylethanolamide
upregulated CDS1 gene concomitant with inhibition of apoptosis
induced by palmitate. (A)Treatment of mouse hepatocytes with
60μM UDCA-LPE for 20 h increased expression of CDS1 but failed to
increase other PC synthesis genes including choline kinase, CDS2,
CEPT2, CEPT, CCTalpha, and PEMT. Quantitative RT-PCR was
performed byTaqMan® RT-PCR with relative expression (ΔRn) of the
target gene versus GAPDH mRNA. Data were representative data
obtained from two different experiments. Data were mean±SD, N =4;
*p<0.05 versus con. (B) A scheme demonstrates metabolism of
phosphatidic acid by CDS1. Intermediate lipids were metabolized by PS
synthase, PS decarboxylase, and ﬁnally PE methyltransferase to result
in increased PC abundance. (C) Co-treatment of UDCA-LPE with
palmitate markedly upregulated expression of CDS1 after 20 h
treatment (left panel). Quantitative RT-PCR was carried out as in (A).
Concomitantly, palmitate-induced apoptosis as determined by caspase
3 activity was signiﬁcantly inhibited by UDCA-LPE (right panel). Data
are mean±SD, N =6; *p<0.05 versus control; §p<0.05 versus
palmitate. “Con” represents control hepatocytes treated with 0.5%
BSA used as a vehicle.
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lyso PC (Pathil et al., 2011a,b). It has been shown that CDS1 activ-
ity is inhibited by lyso PC in vitro (Lin et al., 1991). UDCA-LPE’s
ability to lower lyso PC concentrations may lead to increases
in CDS1 activity and hence increased PC. Increased CDS1 and
PC abundance by UDCA-LPE could also provide dilinoleyl- or
polyenyl PC (Aleynik et al., 1997; Lieber et al., 2003) as well as PC-
containing medium-chain fatty acids, such as dilauroyl PC, which
is a new PC molecule recently identiﬁed to elicit protective anti-
diabetic effects (Lee et al., 2011). Alternatively, UDCA-LPE may
prevent PC export to extracellular space thus allowing more PC
for maintaining cell integrity during stress. Further analyses of PC
export genes affected by UDCA-LPE are still yet to be determined.
It is possible that increases of PC may indicate increased avail-
ability of free fatty acids due to upregulation of lipogenic genes by
drug treatment (Anthérieu et al., 2011). This possibility may be
applicable for treatment longer than 4 h to allow protein transla-
tion. UDCA-LPE’s ability to increase lipogenic genes such as fatty
acid synthase and elongase genes has previously been observed
(unpublished data). These de novo lipogenic lipids including PC
in fact reﬂect the protection against cell death during palmitate
stress after 20 h (Collins et al., 2010; Green and Olsen, 2011). It
has been shown that CDS1 expression is concomitantly increased
with lipogenesis genes fatty acid synthase during fetal lung devel-
opment (Zhang et al., 2004), it is surmised that CDS1 may be
similarly regulated by de novo lipogenesis transcription factors.
As UDCA-LPE elicits lipoprotection after 20 h treatment, UDCA-
LPE may be found most effective in treatment of pathological
acute hepatotoxicity as to compare with normal physiological
conditions. While many cationic amphiphilic drugs such as chlor-
promazine and tamoxifen are known tobe cytotoxic tohepatocytes
by inducing phospholipidosis (Chatman et al., 2009), it is still to
be determined whether UDCA-LPE could accumulate phospho-
lipids in lysosomes (which are the organelles for phospholipido-
sis). As UDCA-LPE targets mitochondria by inhibiting the loss
of mitochondrial membrane potentials (Chamulitrat et al., 2009),
UCDA-LPE may elicit protection during acute liver injury at this
organelle (Pathil et al., 2011a). PC could likely be accumulated in
the mitochondrial membrane for protection.
We herein demonstrated that UDCA-LPE rapidly caused accu-
mulation of hepatic PC likely by stimulation of speciﬁc signaling
pathways of PC metabolism. Further experiments are still yet to
be performed to investigate UDCA-LPE protective effects against
severe hepatotoxicity induced by drugs such as acetaminophen.
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